文献速递前列腺癌

欧洲前列腺癌筛查随机研究风险计算器在中国人群中的适配与外部验证

Adaptation and external validation of the European randomised study of screening for prostate cancer risk calculator for the Chinese population.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2016-11-29

研究将欧洲前列腺癌筛查随机研究(ERSPC)风险计算器3适配于中国人群,在香港两个队列中开发并外部验证。适配后模型对前列腺癌和高分级前列腺癌的区分度良好,校准优秀,决策曲线分析显示净临床获益优于PSA。

要点

  • 适配后的ERSPC风险计算器在中国外部验证队列中校准优秀、区分度良好。
  • 外部验证队列中前列腺癌AUC为0.76,高分级前列腺癌AUC为0.85。
  • 决策曲线分析显示适配模型净临床获益优于PSA。

核心结论

  • 开发了针对中国人群的重新校准ERSPC风险计算器,外部验证显示其区分度、校准和净临床获益均良好。

研究设计与样本

  • 将原始ERSPC风险计算器3应用于开发队列3006例既往未筛查的香港中国男性,年龄50-80岁,PSA 0.4-50 ng/ml,前列腺体积10-150 ml,1997至2015年行初次经直肠活检。
  • 对风险计算器3进行简单适配,并在另一家香港医院的2214例中国男性队列中进行外部验证。

主要发现

  • 开发队列中前列腺癌诊断率为16.7%(503/3006),高分级前列腺癌为7.8%(234/3006)。
  • 验证队列中前列腺癌诊断率为20.2%(447/2204),高分级前列腺癌为9.7%(214/2204)。
  • 开发队列中使用原始风险计算器3模型,前列腺癌AUC为0.75,高分级前列腺癌AUC为0.84,但校准图显示明显高估。
  • 外部验证中重新校准的风险计算器3模型校准优秀,区分度良好,前列腺癌AUC为0.76,高分级前列腺癌AUC为0.85。
  • 验证队列决策曲线分析显示重新校准的风险计算器3模型较PSA有净临床获益。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To adapt the well-performing European Randomized Study of Screening for Prostate Cancer (ERSPC) risk calculator to the Chinese setting and perform an external validation. METHODS: The original ERSPC risk calculator 3 (RC3) for prostate cancer (PCa) and high-grade PCa (HGPCa) was applied to a development cohort of 3006 previously unscreened Hong Kong Chinese men with initial transrectal biopsies performed from 1997 to 2015, age 50-80 years, PSA 0.4-50 ng ml-1 and prostate volume 10-150 ml. A simple adaptation to RC3 was performed and externally validated in a cohort of 2214 Chinese men from another Hong Kong hospital. The performance of the models were presented in calibration plots, area under curve (AUC) of receiver operating characteristics (ROCs) and decision curve analyses. RESULTS: PCa and HGPCa was diagnosed in 16.7% (503/3006) and 7.8% (234/3006) men in the development cohort, and 20.2% (447/2204) and 9.7% (214/2204) men in the validation cohort, respectively. The AUCs using the original RC3 model in the development cohort were 0.75 and 0.84 for PCa and HGPCa, respectively, but the calibration plots showed considerable overestimation. In the external validation of the recalibrated RC3 model, excellent calibration was observed, and discrimination was good with AUCs of 0.76 and 0.85 for PCa and HGPCa, respectively. Decision curve analyses in the validation cohort showed net clinical benefit of the recalibrated RC3 model over PSA. CONCLUSIONS: A recalibrated ERSPC risk calculator for the Chinese population was developed, and it showed excellent discrimination, calibration and net clinical benefit in an external validation cohort.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Chiu PK, Roobol MJ, Nieboer D, et al. Adaptation and external validation of the European randomised study of screening for prostate cancer risk calculator for the Chinese population. Prostate Cancer Prostatic Dis. 2016. PMID: 27897172. doi:10.1038/pcan.2016.57

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。